• 中国科学论文统计源期刊
  • 中国科技核心期刊
  • 美国化学文摘(CA)来源期刊
  • 日本科学技术振兴机构数据库(JST)

JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE ›› 2025, Vol. 27 ›› Issue (2): 234-246.DOI: 10.3969/j.issn.1671-2587.2025.02.014

Previous Articles     Next Articles

New Progress on the Molecular Mechanism of Sema7a Protein

LAI Dongdi1,2,3, ZHONG Minglu1,2,3, DONG Han1,2, PENG Weikang1,2,3, WEI Yaming1,2,3, YUAN Zhaohu1,2,3   

  1. 1Department of Blood Transfusion, Guangzhou First Peoples Hospital, Guangzhou, 510180;
    2Guangdong Engineering Research Centre of Precise Transfusion, Guangzhou, 510180;
    3Research institute of Blood Transfusion and Hematology, Guangzhou Medical University, 510180
  • Received:2024-12-23 Online:2025-04-20 Published:2025-04-17

Abstract: Sema7a protein, a member of the semaphorin protein family, also known as CDw108 or JMH antigen, is a blood group antigen on the surface of erythrocyte membrane. It's a glycosylphosphatidylinositol (GPI)-anchored glycoprotein widely expressed on the cell membranes of various tissues throughout the body. The Sema7a protein can be cleaved from cell membrane by various physical and chemical factors, such as enzyme, blood shear force and hypoxia. The Sema7a protein on the surface of erythrocyte membrane is the main source of free Sema7a in vivo. The Sema7a protein can bind to two known receptors, integrin or PlexinC1 (PlexinC1), or in a free form to participate in various biological activities throughout the body, and plays an important role in cell differentiation, nerve signal transduction, immune response, inflammation regulation, and tumor progression. This review summarizes the mechanisms of Sema7a protein involvement in the occurrence and development of different diseases based on the classification of systemic disease.

Key words: Sema7a, JMH antigen, Integrin, Plexin C1

CLC Number: